# Grace Therapeutics, Inc.: Form 20-F for the period ended Mar 31, 2019

- Company: [Grace Therapeutics, Inc.](/companies/grce.md) (CIK 1444192)
- Form: 20-F
- Filed: 2019-06-26
- Accepted by EDGAR: Jun 26, 2019, 08:12 ET
- Period: 2019-03-31
- Accession: 0001171843-19-004174
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1444192/000117184319004174/f20f_062519p.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1444192/000117184319004174/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Operating cash flow | 12 months, 2018-04-01 to 2019-03-31 | −CAD 32.5m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2018-04-01 to 2019-03-31 | CAD 700.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Shares outstanding | at 2019-03-31 | 78,132,734 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1444192/000117184319004174/f20f_062519p.htm

Filed Jun 26, 2019.
Source: SEC EDGAR, the filing index for accession 0001171843-19-004174. Last ingested by Listed: Nov 14, 2026, 23:10 ET. No prices; not investment advice.
